Alliant Energy Corporation Announces Second Quarter Earnings Release and Conference Call
Alliant Energy will webcast the event live at www.alliantenergy.com/investors. The call is open to the public and will be hosted by Lisa Barton, President and CEO; and Robert Durian, Executive Vice President and CFO. Individuals who would like to participate in the conference call can do so by dialing (800) 549-8228 (Toll Free – North America) or (646) 564-2877 (International). The conference ID is 78071.
An archive of the webcast will be available on the company's website at www.alliantenergy.com/investors.
Alliant Energy Corporation (NASDAQ: LNT) provides regulated energy service to approximately 1 million electric and 430,000 natural gas customers across Iowa and Wisconsin. Alliant Energy's mission is to deliver energy solutions and exceptional service customers and communities count on – safely, efficiently and responsibly. Interstate Power and Light Company (IPL) and Wisconsin Power and Light Company (WPL) are Alliant Energy's two public energy companies. Alliant Energy is a component of Bloomberg's Gender-Equality Index and the S&P 500. For more information, visit alliantenergy.com and follow Alliant Energy on LinkedIn, Facebook, Instagram and X.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
27 minutes ago
- Yahoo
How Unusual Options Standout Boston Scientific (BSX) is Signaling a Statistical Edge
Undeniably, Barchart's screener for unusual stock options volume is an important tool for deciphering market sentiment, especially among the voices that matter. Indeed, the smart money is akin to battleground states. Sure, California and New York represent the nation's economic engine. But it's states like Pennsylvania and Georgia that ultimately determine the presidency. Still, it's not a perfect analogy because unusual options screeners can be deceiving. For example, put/call ratios provide a potential clue as to the smart money's motivations. At the same time, derivatives can be bought or sold, thus changing whether the position is debit based or credit based. Moreover, an elevated volume of calls doesn't necessarily imply bullishness nor does heightened put activity necessarily imply bearishness. Chevron Stock's 4.6% Dividend Yield and 1.67% One Month Short Put Yield Make CVX a Buy Trading DAL Earnings? This Naked Put Play Benefits from Volatility Constellation Brands Stock is Down But Produced Good Earnings - Is STZ a Buy Here? Our exclusive Barchart Brief newsletter is your FREE midday guide to what's moving stocks, sectors, and investor sentiment - delivered right when you need the info most. Subscribe today! Further, not every security generating unusual options activity is going to be statistically intriguing. Frankly, many if not most names that look attractive are simply generating noise. A select few are genuinely tempting — and it's my belief that we can deploy Markovian frameworks and probabilistic analyses to separate the wheat from the chaff. We'll dive into this concept soon enough. For now, investors may want to zero in on Boston Scientific (BSX). A specialist in medical devices, BSX stock has been a solid performer. Since the start of this year, the equity gained nearly 17%. For context, the benchmark S&P 500 index is up only less than 7% during the same frame. Even better, those who missed the boat may have an opportunity for a do-over. On Thursday, total options volume for BSX stock reached 15,589 contracts, representing a 33.39% lift over the trailing one-month average. Call volume hit 11,368 contracts while put volume sat at only 4,221 contracts. This pairing yielded a put/call ratio of 0.37, which in theory favors optimistic traders. Still, as I mentioned earlier, investors need to be careful of reading too deeply into the ratio. It's here that options flow — a screener that focuses exclusively on big block transactions likely placed by institutional investors — can be instructive. Heading into the holiday weekend, net trade sentiment clocked in at $378,800 above parity, distinctly favoring the bulls. As compelling as the unusual options data is, the screener alone doesn't always provide a clear framework for when an anticipated move may materialize. Usually, transactions in the derivatives market feature multiple expiration dates, making inferences difficult. To remedy this challenge, we can apply statistical analysis. Unfortunately, statistics is a deceptively difficult practice in the investment markets. Taking the frequency of the desired outcome divided by the total number of events merely calculates the derivative probability or the outcome odds across the underlying dataset's entire distribution. What we're looking for is the conditional probability — the outcome odds across a specific subset of the data. However, conditional probabilities really can't be calculated using share price or its many derivatives because of the continuous signal problem. Another remedy must occur and that is the process of discretization — converting scalar signals into discrete states. This is where market breadth or sequences of accumulative and distributive sessions comes into play. In the past two months, the price action of BSX stock can be converted as a 4-6-U sequence: four up weeks, six down weeks, with a positive trajectory across the 10-week period. Admittedly, this conversion process compresses BSX's magnitude dynamism into a simple binary code. But the benefit is that this code segregates price action into distinct, discrete behavioral states — forming the basis for Markovian analysis. Essentially, we're looking for the likelihood of sentiment transition based off the 4-6-U sequence. From past analogs, we know that this sequence materialized 17 times since January 2019. Notably, in 64.71% of cases, the following week's price action results in upside, with a median return of 1.79%. Should the bulls maintain control of the market for a second week, investors may anticipate an additional performance boost of around 1.1%. Based on last Thursday's close of $104.32, BSX stock could potentially crack above the $107 level within the next two weeks. For those who want to roll the dice on the statistical narrative above, the 105/107 bull call spread expiring July 18 could be enticing. This transaction involves buying the $105 call and simultaneously selling the $107 call, for a net debit paid of $100, the most that can be lost in the trade. Should BSX stock rise through the short strike price ($107) at expiration, the maximum reward is also $100, a payout of 100%. Primarily, what makes this trade attractive is the implied shift in sentiment regime of the 4-6-U sequence. Ordinarily, BSX stock enjoys a fairly robust upside bias. As a baseline, the chance that a long position on any given week will be profitable is 56.47%. However, the 4-6-U adds 8.24 percentage points of favorable odds for the bullish speculator. To be clear, no forecasting model is perfect, particularly because the stock market is an open system, which means that outside catalysts can enter the paradigm and disrupt it. Still, the discretization process mentioned earlier for the purpose of applying Markovian principles helps us to empirically quantify our decision-making process. On the date of publication, Josh Enomoto did not have (either directly or indirectly) positions in any of the securities mentioned in this article. All information and data in this article is solely for informational purposes. This article was originally published on
Yahoo
27 minutes ago
- Yahoo
Could Apple Soon Lose Its Top Position in Warren Buffett's Portfolio?
Apple has been one of Warren Buffett's largest holdings for years, but the distance between second spot has been shrinking. Buffett has been unloading Apple stock and it has also been falling in value. 10 stocks we like better than Apple › Warren Buffett has famously referred to iPhone maker Apple (NASDAQ: AAPL) as "probably the best business I know in the world." It's long been one of Buffett's favorite stocks, and it has been a staple in the Berkshire Hathaway (NYSE: BRK.A)(NYSE: BRK.B) portfolio for years. But while it still remains the top holding in the portfolio, it may not stay in that position for much longer. Here's why that could happen and what it might mean for investors. It wasn't all that long ago when Apple was easily the largest holding in Berkshire's portfolio, and it wasn't even close. As of the end of 2023, Apple accounted for half of the entire portfolio and was worth more than $174 billion. The next-largest holding was Bank of America, which accounted for just 10% of the portfolio and was worth a little less than $35 billion at the time. The idea of Apple falling in the second spot just didn't look like a conceivable scenario. However, with Buffett selling Apple stock since then and shares of the tech giant also falling, that has resulted in a much different makeup of Berkshire's portfolio today. Berkshire's position in Apple has been trimmed by two-thirds and was worth nearly $67 billion as of the end of March. While that was still good enough for the top spot and represented 26% of all holdings, the second spot, which belonged to American Express, accounted for 16% of the portfolio and was worth nearly $41 billion. Today, the gap is even thinner, with Apple's share of the Berkshire portfolio coming in at just under 22% versus nearly 17% for American Express. Apple has been a beloved Buffett stock for years, but amid fears of a rising capital gains tax rate, the billionaire investor has been drastically reducing his company's position in the tech giant. Even if Buffett doesn't sell any more Apple shares, the stock's falling valuation could lead to it falling to the second-largest holding in the fund in the near future. Shares of Apple are down 6% over the past 12 months, while American Express has risen by more than 37% over that stretch (returns as of July 7). Investors have been bearish on Apple over the slow rollout of artificial intelligence (AI) features for its latest iPhone. Without a drastic change and a way to convince investors that it's still a good growth stock and the business isn't falling behind its rivals, this downward trend may continue. In the longer term, I could see Apple even leaving the Berkshire portfolio permanently. Buffett is stepping down as CEO this year, at which point Greg Abel will take over. Under new leadership, there could be greater changes ahead, including potentially exiting the company's position in Apple and opting for stocks that may be better positioned for growth in AI. While that's not a guarantee, it may be a plausible scenario, especially if Apple struggles to show that it can keep up with its key competitors. Whether Apple is or isn't in Berkshire's portfolio shouldn't dictate whether you buy the stock or not. It may impact the stock in the short term as Buffett fans may follow suit and sell shares of Apple as well. Ultimately, however, whether you buy the stock or not should depend on your long-term investing strategy. If you're willing to be patient and invest in a blue chip stock that has phenomenal financials, including annual free cash flow of around $100 billion, then this can be a good investment to put into your portfolio today. While it may be a volatile road ahead for Apple, with a strong ecosystem of products and ample resources at its disposal, I'm confident the company can be a big player in AI and turn things around -- it's just a matter of how long it may take for that to happen. Before you buy stock in Apple, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Apple wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $695,481!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $969,935!* Now, it's worth noting Stock Advisor's total average return is 1,053% — a market-crushing outperformance compared to 179% for the S&P 500. Don't miss out on the latest top 10 list, available when you join . See the 10 stocks » *Stock Advisor returns as of July 7, 2025 Bank of America is an advertising partner of Motley Fool Money. American Express is an advertising partner of Motley Fool Money. David Jagielski has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Apple, Bank of America, and Berkshire Hathaway. The Motley Fool has a disclosure policy. Could Apple Soon Lose Its Top Position in Warren Buffett's Portfolio? was originally published by The Motley Fool Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
27 minutes ago
- Yahoo
Cogent Biosciences Announces Pricing of Upsized Public Offering of Shares of Common Stock
WALTHAM, Mass. and BOULDER, Colo., July 08, 2025 (GLOBE NEWSWIRE) -- Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined diseases, today announced the pricing of its previously announced underwritten public offering of 22,222,223 shares of its common stock, offered at a public offering price of $9.00 per share. The aggregate gross proceeds to Cogent from this offering are expected to be approximately $200 million, before deducting underwriting discounts and commissions and other offering expenses. In addition, Cogent has granted the underwriters a 30-day option to purchase up to an additional 3,333,333 shares of its common stock on the same terms and conditions. All of the securities in the offering are being sold by Cogent. The offering is expected to close on or about July 10, 2025, subject to the satisfaction of customary closing conditions. Cogent intends to use the net proceeds from the offering for continued development, regulatory and commercial preparation activities relating to bezuclastinib and other product candidates, activities to support the planned commercial launch of bezuclastinib as well as for working capital and general corporate purposes. J.P. Morgan, Leerink Partners and Guggenheim Securities are acting as joint book-running managers for the offering. LifeSci Capital is also acting as lead manager for the offering. The securities described above are being offered pursuant to an automatic shelf registration statement on Form S-3ASR (File No. 333-269707), which was filed with the Securities and Exchange Commission (SEC) on February 10, 2023 and automatically became effective upon filing. A preliminary prospectus supplement and accompanying base prospectus relating to and describing the terms of the offering were filed with the SEC on July 8, 2025. A final prospectus supplement and the accompanying base prospectus relating to and describing the terms of the offering will be filed with the SEC. The securities described above have not been qualified under any state blue sky laws. This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or jurisdiction. The offering can be made only by means of a prospectus supplement and accompanying base prospectus, copies of which may be obtained at the SEC's website at or by request to J.P. Morgan Securities LLC, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, or by email at prospectus-eq_fi@ and postsalemanualrequests@ Leerink Partners LLC, Attention: Syndicate Department, 53 State Street, 40th Floor, Boston, MA 02109, by telephone at (800) 808-7525, ext. 6105, or by email at syndicate@ or Guggenheim Securities, LLC, Attention: Equity Syndicate Department, 330 Madison Ave., New York, NY 10017, or by telephone at (212) 518-9544, or by email at GSEquityProspectusDelivery@ About Cogent Biosciences, Inc. Cogent Biosciences is a biotechnology company focused on developing precision therapies for genetically defined diseases. The most advanced clinical program, bezuclastinib, is a selective tyrosine kinase inhibitor that is designed to potently inhibit the KIT D816V mutation as well as other mutations in KIT exon 17. KIT D816V is responsible for driving systemic mastocytosis, a serious disease caused by unchecked proliferation of mast cells. Exon 17 mutations are also found in patients with advanced gastrointestinal stromal tumors, a type of cancer with strong dependence on oncogenic KIT signaling. The company also has an ongoing Phase 1 study of its novel internally discovered FGFR2 inhibitor. In addition, the Cogent Research Team is developing a portfolio of novel targeted therapies to help patients fighting serious, genetically driven diseases targeting mutations in ErbB2, PI3Kα and KRAS. Cogent Biosciences is based in Waltham, MA and Boulder, CO. Forward-looking Statements This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical facts, contained in this press release, including statements regarding the completion of the public offering and the use of proceeds therefrom, are forward-looking statements. The use of words such as, but not limited to, 'anticipate,' 'believe,' 'continue,' 'could,' 'estimate,' 'expect,' 'intend,' 'may,' 'might,' 'plan,' 'potential,' 'predict,' 'project,' 'should,' 'target,' 'will,' or 'would' and similar words or expressions are intended to identify forward-looking statements. Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based on our current beliefs, expectations and assumptions regarding the future of our business, future plans and strategies, our clinical results, the rate of enrollment in our clinical trials and other future conditions. New risks and uncertainties may emerge from time to time, and it is not possible to predict all risks and uncertainties. No representations or warranties (expressed or implied) are made about the accuracy of any such forward-looking statements. We may not actually achieve the forecasts or milestones disclosed in our forward-looking statements, and you should not place undue reliance on our forward-looking statements. Such forward-looking statements are subject to a number of material risks and uncertainties including but not limited to our capital position and the sufficiency of our capital to fund our operations in future periods; our use of the net proceeds of the underwritten public offering; risks and uncertainties related to market conditions and the satisfaction of customary closing conditions related to the underwritten public offering; the impact of general economic, health, industrial or political conditions in the United States or internationally; and other risks and uncertainties identified in our filings with the SEC, including our Registration Statement on Form S-3ASR, which was filed with the SEC on February 10, 2023 and automatically became effective upon filing, as may be amended from time to time, together with the accompanying base prospectus contained therein and the documents incorporated by reference therein, including our most recent Annual Report on Form 10-K, our Quarterly Report on Form 10-Q and our subsequent periodic reports filed with the SEC, and the preliminary prospectus supplement related to this offering. Any forward-looking statement speaks only as of the date on which it was made. Neither we, nor our affiliates, advisors or representatives, undertake any obligation to publicly update or revise any forward-looking statement, whether as result of new information, future events or otherwise, except as required by law. These forward-looking statements should not be relied upon as representing our views as of any date subsequent to the date hereof. Contact: Christi WaarichSenior Director, Investor
